Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NPSP795

Phase 2Small molecule

NPSP795 is one of 11 small molecule programs targeting Hypocalcemia. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypocalcemiaActive, not recruiting

HypocalcemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hypocalcemia

#DrugCompanyPhaseTrials

Calciferol

Alnylam Pharmaceuticals

Zemplar

Forteo

Rocaltrol

Alnylam Pharmaceuticals

Calcium

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Deltavit

HHyundai Pharmaceutical Co., LTD.

Encaleret

CCalcilytix Therapeutics, Inc., a BridgeBio company

Tums

NPSP795

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypocalcemia1 trial

A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations

Completed· Takeda logo

Takeda·Phase 2·NCT02204579·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NPSP795. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPSP795 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPSP795. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

Related News